Abstract:Human genome sequencing studies have identified numerous loci associated with complex diseases, including Alzheimer’s disease (AD). However, translating human genetic and genomic findings (i.e., genome‐wide association studies [GWAS]) to pathobiology and therapeutic discovery remains a major challenge. Today, artificial intelligence and deep learning approaches that identify new risk genes and drug targets from human genome sequencing findings are enabling a more complete mechanistic understanding of disease biology. This is facilitating more rapid development of targeted therapeutic interventions for AD. We presented a network topology‐based deep learning framework to identify disease‐associated genes (NETTAG). NETTAG integrates multi‐genomics data and the human protein‐protein interactome to infer putative risk genes and drug targets impacted by GWAS loci. Specifically, we leveraged non‐coding GWAS loci effects on expression quantitative trait loci (eQTLs), histone‐QTLs, transcription factor binding‐QTLs, enhancers and CpG islands, promoter regions, open chromatin, and promoter flanking regions. The fundamental premise of NETTAG is that disease risk genes exhibit distinct functional characteristics compared to non‐risk genes, and can therefore be distinguished by their aggregated genomic features under the human protein interactome. Applying NETTAG to the latest AD GWAS data, we identified 156 putative AD‐risk genes (i.e., APOE, BIN1, GSK3B, MARK4, and PICALM). We showed that predicted risk genes are: 1) significantly enriched in AD‐related pathobiological pathways, 2) more likely to be differentially expressed in transcriptomes and proteomes of AD brains, and 3) enriched in druggable targets with approved medicines. Specifically, we showed that NETTAG‐predicted genes (e.g., MEF2D, CPLX2, KLF4, ACTL6B, P2RX7 and etc.) are differentially expressed in AD‐associated microglia and astrocytes from single‐nuclei RNA‐sequencing data of human postmortem brains with varying degrees of AD neurobiology. Via network‐based prediction, we identified multiple repurposable drug candidates (i.e., choline, deferoxamine and ibudilast) for potential treatment of AD. Our findings suggest that understanding human pathobiology and therapeutic development could benefit from network‐based deep learning methodology that utilizes GWAS findings with multimodal genomic analyses.

Deep Learning-Based Polygenic Risk Analysis for Alzheimer’s Disease Prediction

Deep learning-based polygenic risk analysis for Alzheimer's disease prediction

Deep learning methods improve polygenic risk analysis and prediction for Alzheimer’s disease

Deep learning for polygenic score analysis for Alzheimer's disease risk prediction in the Chinese population.

Assessing polyomic risk to predict Alzheimer's disease using a machine learning model

Alzheimer’s disease risk prediction using automated machine learning

Deep Post-Gwas Analysis Identifies Potential Risk Genes and Risk Variants for Alzheimer’s Disease, Providing New Insights into Its Disease Mechanisms

Polygenic Hazard Score Associated Multimodal Brain Networks along the Alzheimer's Disease Continuum.

Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study

Explainable machine learning aggregates polygenic risk scores and electronic health records for Alzheimer’s disease prediction

Identifying Genes Associated with Alzheimer's Disease Using Gene-Based Polygenic Risk Score

Deep Neural Network Classifier for Alzheimer’s Disease

DEEP LEARNING APPLICATION IN IDENTIFYING PROTEOMIC RISK MARKERS FOR ALZHEIMER’S DISEASE

DeepRisk: A deep learning approach for genome-wide assessment of common disease risk

Classifying Alzheimer's disease and normal subjects using machine learning techniques and genetic-environmental features

Epistatic Features and Machine Learning Improve Alzheimer's Disease Risk Prediction Over Polygenic Risk Scores

A Network‐based Deep Learning Framework Translates GWAS and Multi‐Omics Findings to Pathobiology and Drug Repurposing for Alzheimer’s Disease

Prediction of Alzheimer’s disease-specific phospholipase c gamma-1 SNV by deep learning-based approach for high-throughput screening

A simulative deep learning model of SNP interactions on chromosome 19 for predicting Alzheimer's disease risk and rates of disease progression

Comparative analysis of machine learning algorithms for Alzheimer's disease classification using EEG signals and genetic information

Deep Learning-Based Prediction of Alzheimer's Disease Using Microarray Gene Expression Data